CBD and Your Medications

The enzyme system CBD and grapefruit share

Most oral medications leave your body only after a family of liver enzymes called cytochrome P450, or CYP450, breaks them down. Different members of that family handle different drugs, which is why one interaction warning rarely applies to everything in your medicine cabinet.

Cannabidiol's own FDA-approved prescribing label — for Epidiolex, the only CBD product the FDA has ever approved — states that “cannabidiol is metabolized in the liver and the gut, primarily in the liver, by CYP2C19 and CYP3A4 enzymes.” CBD doesn't just get processed by those enzymes; the same label says it acts on several of them in the other direction, too:

• CYP1A2 — cannabidiol is a weak inhibitor.
• CYP2C19 — cannabidiol is a moderate inhibitor.
• CYP2B6 — cannabidiol is both an inducer and an inhibitor, an unusual dual profile.
• CYP2C8 — the label warns of potentially “clinically significant interactions.”
• UGT1A9 — a separate, non-CYP liver enzyme; cannabidiol inhibits it too.

None of that is theoretical. It's the language the FDA approved for cannabidiol's own drug label, current as of the May 2026 revision.

Why the grapefruit warning is worth borrowing

The FDA explains the grapefruit warning in plain terms: “Many drugs are broken down (metabolized) with the help of a vital enzyme called CYP3A4 in the small intestine. Grapefruit juice can block the action of intestinal CYP3A4, so instead of being metabolized, more of the drug enters the blood and stays in the body longer.” As FDA's Dr. Shiew Mei Huang put it, “when there is too much drug in the blood, you may have more side effects.”

The FDA has required grapefruit warnings on drugs across several categories for exactly this reason. Examples the agency names directly:

(Grapefruit also affects a couple of drugs, like the allergy medicine Allegra, through a completely different mechanism — blocking a transporter instead of an enzyme — and the FDA calls that distinction out specifically. It's a good reminder that mechanism, not just the word “interaction,” is what actually matters.)

CBD is metabolized by, and can affect, that same CYP3A4 enzyme — confirmed in cannabidiol's own FDA-approved label, not just in theory. Nobody has run a grapefruit-style clinical study substituting CBD for grapefruit juice, so this isn't proof that CBD affects your specific drug by the same amount, or even in the same direction. But if your prescription already carries a grapefruit warning, you already know that drug is sensitive to this pathway. That's the shortcut worth remembering: let an existing grapefruit warning be your cue to ask about CBD too, not a diagnosis on its own.

What the one FDA-approved CBD medicine says about itself

Epidiolex is the only CBD product the FDA has approved, for seizures linked to Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Its prescribing label is the single most direct piece of regulatory evidence that exists about CBD and other drugs, because it was tested specifically for this, in patients and healthy volunteers, not inferred from theory.

Some of what its trials measured, in the label's own numbers:

• Caffeine, a CYP1A2 test drug, was absorbed 95% more (AUC) when taken with Epidiolex than alone.
• Clobazam, an anti-seizure drug often prescribed alongside Epidiolex, had its active byproduct rise roughly three-fold.
• Everolimus, an immunosuppressant, rose about two-and-a-half-fold in exposure.
• Bupropion, cleared by CYP2B6, actually went down about 20% — these effects don't all point the same direction.
• Tolbutamide (a CYP2C9 test drug) and midazolam (a CYP3A4 test drug) showed no meaningful change at the doses Epidiolex's own trials used.

The same label documents dose-related rises in liver enzymes: about 13% of Epidiolex patients crossed three times the normal upper limit for ALT, versus 1% on placebo. That rate climbs to about 30% when Epidiolex is combined with both clobazam and a second anti-seizure drug called valproate, compared with roughly 3% of patients on neither. It's why Epidiolex prescribing includes scheduled bloodwork — before starting, then at one, three, and six months.

One more detail matters more than people expect: how much CBD actually reaches your bloodstream isn't fixed. The label shows a high-fat meal roughly quadruples its absorption compared with an empty stomach, and alcohol increases it by about 63%. Two people taking what looks like “the same dose” can end up with very different amounts of CBD actually circulating, which is one more reason a flat answer isn't an honest one — see our dosage guide for how we think about that generally.

Here's where it gets genuinely messy. In Epidiolex's own trial, a single dose of midazolam (a classic CYP3A4 test drug) showed no significant change when taken with Epidiolex at 750 mg twice daily. But a separate study run at Johns Hopkins, published in Clinical Pharmacology & Therapeutics in 2023, gave healthy adults a single 640 mg dose of CBD (with a small amount of THC) and found the opposite: a 56% rise in that same midazolam test, a 77% rise in a CYP2C9 test drug, and a 207% rise in a CYP2C19 test drug. THC alone, tested the same way, changed nothing — so the effect tracked CBD, not THC. Two credible studies, two different doses and forms, two different answers. That's not a reason to stop asking the question. It's the honest shape of what's actually known.

The FDA has said much the same thing in plainer language. Its own consumer guidance on CBD states: “Taking CBD with other medications may increase or decrease the effects of the other medications … We are concerned about the potential safety of taking other medicines with CBD when not being monitored by a healthcare provider.” That's the FDA, about the one CBD product it has actually reviewed, in guidance it has not withdrawn.

Four categories where a real conversation matters most

Some categories of medication show up again and again in the case reports and clinical trials that exist so far. None of this is a reason to panic if you take one of these — it's a reason to have the conversation before you start, not after.

Blood thinners. Warfarin's more potent form is cleared mainly by CYP2C9, and its weaker form by CYP1A2 and CYP3A4 — a group CBD can influence. The evidence is real but wildly dose-dependent: in one published case, a man's warfarin dose had to be cut by about 30% after he started an Epidiolex-level CBD regimen for epilepsy, because his INR (a measure of how slowly his blood was clotting) climbed. In a separate case, an 85-year-old on a much lower daily CBD dose (about 5 mg) saw almost no change in INR over eleven months. Epidiolex's label separately notes that CBD can run the other direction for a related drug, clopidogrel, by lowering its active form — meaning less protection, not more bleeding risk. Either direction is a reason to have levels checked, not guessed at.

Anti-seizure medication. This is the best-documented category, for the simple reason that Epidiolex is itself an anti-seizure drug and its trials tested exactly this combination. Adding it to clobazam raised clobazam's active metabolite roughly three-fold; adding it to both clobazam and valproate raised the odds of a significant liver enzyme rise to about 30%, versus roughly 3% on neither drug. Anyone on an anti-seizure regimen should tell their neurologist about CBD use of any kind, and expect a conversation about monitoring.

Certain antidepressants. A 2026 clinical trial gave healthy adults a CBD dose the researchers described as approximating typical consumer use, alongside citalopram, a common SSRI. Citalopram levels in the blood rose 43%, through the same CYP2C19 pathway, a change the authors compared in size to a known interacting drug. The same trial tested morphine alongside CBD and found almost nothing — a reminder that this is drug-specific, not a blanket CBD effect. A 43% rise in an SSRI isn't automatically dangerous for a given person, but it's exactly the kind of change a prescriber should know about beforehand.

Immunosuppressants. Epidiolex's label names this risk directly: everolimus exposure rose two-and-a-half-fold, and the label flags sirolimus, tacrolimus, and digoxin as likely affected through the same pathway. A 2025 clinical trial tested that prediction directly, dosing healthy volunteers with CBD the same way Epidiolex is dosed, and found tacrolimus levels rose more than three-fold. The same researchers pointed out that their CBD dose was well above the median over-the-counter dose reported by CBD users elsewhere — roughly twenty times higher — so how big this effect is at a typical consumer serving is genuinely unknown, not zero. Anti-rejection drugs have very little margin for error in either direction, which makes this a call-your-transplant-pharmacist-first situation, not a wait-and-see one.

What about birth control?

This comes up often enough to deserve its own answer, and the honest answer is that we don't fully have one. Hormonal contraceptives — the pill, the patch, the ring — rely on ethinyl estradiol and a progestin, both cleared in part through the same CYP3A4 enzyme this whole topic keeps coming back to.

This isn't a hypothetical concern for plant-based supplements in general. St. John's Wort, another over-the-counter herbal product, is a well-documented CYP3A4 inducer, and a published systematic review found real reports of breakthrough bleeding and unintended pregnancy in people taking it alongside hormonal contraceptives. That's the kind of outcome this category of interaction can actually produce.

What we don't have is a clean answer for CBD specifically, and the research that exists on the mechanism doesn't even agree on the direction. An enzyme inducer, like St. John's Wort, would lower hormone levels — the failure-risk story most people have heard. An enzyme inhibitor would do the opposite, raising hormone levels and shifting the concern toward estrogen-related side effects instead. Epidiolex's own single-dose trial found no significant effect on a CYP3A4 test drug; independent research at a different CBD dose found meaningful CYP3A4 inhibition. So even the direction isn't settled, let alone the size.

There is a study built to answer this directly: a randomized trial funded by the Society of Family Planning, measuring CBD's effect on birth-control hormone levels in actual pill users. It finished collecting data in March 2022. As of this writing, no results have been posted to its public trial registry and we could not find a published paper describing what it found. The direct answer has been sitting unanswered for years, and we'd rather tell you that plainly than write a confident-sounding paragraph that isn't backed by it.

If a hormonal method is your main form of contraception and you're considering CBD, this is a question for whoever manages your birth control specifically. Using a backup method is the standard, conservative move any time a possible interaction with birth control hasn't been ruled out — true of plenty of drug classes, not just CBD.

What we'd tell a friend

• Bring your whole list, not just the “important” drugs. Prescriptions, over-the-counter medications, and supplements — a pharmacist can only check what you tell them about.
• Ask a pharmacist specifically, and ask for free. Checking a medication list against CBD takes minutes, doesn't require a doctor's appointment, and is a normal part of what pharmacists do all day.
• If anything on your list already carries a grapefruit warning, lead with that. It's the fastest way to point the conversation at the right drugs.
• On blood thinners, anti-seizure medication, certain antidepressants, or an anti-rejection drug, ask before you start. These are the categories with real, published evidence of interactions — not a reason to panic, but not a “probably fine” either.
• Spacing doses apart during the day doesn't fix this kind of interaction. These are metabolic effects in the liver, not two substances meeting in your stomach, so timing tricks that help with some other supplements don't reliably apply here.
• Tell every prescriber, not just one. If a specialist manages the medication that matters most, they're the one who needs to know.

Where the evidence is honestly still thin

Almost every number in this article comes from Epidiolex, dosed at 10 to 25 mg per kilogram of body weight per day and monitored with scheduled bloodwork. A commonly cited survey of long-term CBD users put the median self-reported over-the-counter dose at about 0.6 mg per kilogram per day — roughly a twentieth of Epidiolex's upper range. That gap matters, and it cuts both ways.

It doesn't mean these interactions only exist at prescription strength. Some of the mechanisms behave more like an on/off switch than a dial — an enzyme is meaningfully blocked or it isn't — and how much CBD reaches your bloodstream in the first place can swing several-fold based on whether you took it with food. “I only take a little” isn't a guarantee of a proportionally smaller effect.

It also means nobody has directly measured most of these specific drug pairs at the dose most people actually take. Confidence is genuinely lower at consumer doses than at pharmaceutical ones, in both directions. And for at least one everyday question — hormonal contraceptives — the study designed to give a direct answer has been finished for years without a published result. We'd rather say that plainly than paper over it.

None of this is a reason to assume the worst about a specific combination. It's a reason to ask someone who can actually look at your medication list — which is not us, and isn't a search engine either.

FAQ